Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Overview | Financials
Company Name Atara Biotherapeutics, Inc.
Symbol ATRA
Currency USD
Price 6.61
Market Cap 38,071,948
Dividend Yield 0%
52-week-range 5.4 - 20.825
Industry Biotechnology
Sector Healthcare
CEO Dr. Pascal Touchon D.V.M.
Website https://www.atarabio.com

An error occurred while fetching data.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic

Related Stocks

Immatics N.V. logo

Immatics N.V.

IMTX

4.45 USD

Immunovant, Inc. logo

Immunovant, Inc.

IMVT

19.61 USD

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

KPTI

7.44 USD

Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc.

NAUT

1.13 USD

2seventy bio, Inc. logo

2seventy bio, Inc.

TSVT

4.95 USD

Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCT

13.21 USD

Cara Therapeutics, Inc. logo

Cara Therapeutics, Inc.

CARA

5.125 USD

Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc.

NRIX

13.9 USD

MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT

3.47 USD

Financials

Numbers are in millions USD

Numbers are in millions USD